Details

Indicated for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of recurrence and a Ki-67 score >=20% as determined by an FDA approved test.

type

FDA Approval

approval date

2021-10-12

settings
settings
Adjuvant
settings
Early stage
settings
High risk
settings
Lymph node involvement
source

FDA